Inhibition of JAK/STAT3 or PI3k/AKT/mTOR pathways, which have shown potential therapeutic implications in DLBCL [228,229,230], may also ultimately impact PD-L1 expression in the tumour cells [132,231,232], providing additional rationale for future clinical evaluation with PD-1/PD-L1 blockade combinations. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.